Get the Stockscreener App
29.56
6.64%
1.84
After Hours:
29.58
0.02
+0.07%
Lenz Therapeutics Inc stock is traded at $29.56, with a volume of 1.01M.
It is up +6.64% in the last 24 hours and down -11.92% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$27.72
Open:
$27.69
24h Volume:
1.01M
Relative Volume:
1.09
Market Cap:
$924.93M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-5.2811
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
+15.47%
1M Performance:
-11.92%
6M Performance:
+4.99%
1Y Performance:
-13.87%
1-Day Range:
$27.44
$30.25
1-Week Range:
$25.00
$30.25
52-Week Range:
$16.54
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
29.56 | 867.36M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Building trade automation scripts for LENZ Therapeutics Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock By Investing.com - Investing.com South Africa
How LENZ Therapeutics Inc. stock reacts to oil prices2025 Price Targets & High Return Stock Watch Alerts - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock - Investing.com
Officer Olsson Sells 10,000 ($261K) Of LENZ Therapeutics Inc [LENZ] - TradingView
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsEarnings Risk Report & Technical Confirmation Alerts - newser.com
Is LENZ Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsRate Hike & Precise Swing Trade Entry Alerts - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Chart overlay techniques for tracking LENZ Therapeutics Inc.Weekly Volume Report & Capital Protection Trading Alerts - newser.com
How interest rate cuts could boost LENZ Therapeutics Inc. stockWall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Will LENZ Therapeutics Inc. stock see PE expansionJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
How LENZ Therapeutics Inc. stock trades before earnings2025 Trading Recap & AI Driven Price Predictions - newser.com
Has LENZ Therapeutics Inc. formed a bullish divergenceQuarterly Earnings Summary & Safe Entry Zone Identification - newser.com
Is LENZ Therapeutics Inc. trending in predictive chart models2025 Short Interest & Real-Time Chart Pattern Alerts - newser.com
Favourable Signals For LENZ Therapeutics: Numerous Insiders Acquired Stock - 富途牛牛
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):